Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 3/2010

01-06-2010

Bone Changes and Fracture Risk in Individuals Infected With HIV

Authors: Amy H. Warriner, Michael J. Mugavero

Published in: Current Rheumatology Reports | Issue 3/2010

Login to get access

Abstract

The life expectancy of individuals infected with HIV has improved greatly since the institution of combination antiretroviral therapy. However, many metabolic derangements have been discovered with long-term combination antiretroviral treatment, including lipodystrophy; insulin resistance; and, more recently, abnormal bone metabolism. It is well-documented that bone mineral density (BMD) in HIV-positive patients is lower compared with the expected BMD in non–HIV-positive patients. The underlying cause of lower BMD is unknown but is thought to be a multifactorial process. Conflicting evidence exists regarding the effect of antiretroviral exposure and duration of treatment, antiretroviral type, and cumulative HIV viral exposure on bone health. Here we review the bone changes that occur with HIV infection and treatment.
Literature
1.
Brown TT, Ruppe MD, Kassner R, et al.: Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab 2004, 89:1200–1206.CrossRefPubMed
2.
Bruera D, Luna N, David DO, et al.: Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003, 17:1917–1923.CrossRefPubMed
3.
Mondy K, Yarasheski K, Powderly WG, et al.: Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus–infected individuals. Clin Infect Dis 2003, 36:482–490.CrossRefPubMed
4.
Nolan D, Upton R, McKinnon E, et al.: Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 2001, 15:1275–1280.CrossRefPubMed
5.
Tebas P, Powderly WG, Claxton S, et al.: Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000, 14:F63–F67.CrossRefPubMed
6.
Prior J, Burdge D, Maan E, et al.: Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study. Osteoporos Int 2007, 18:1345–1353.CrossRefPubMed
7.
•• Triant VA, Brown TT, Lee H, Grinspoon SK: Fracture prevalence among human immunodeficiency virus (HIV)–infected versus non–HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008, 93:3499–3504. This study provides an estimate of fracture occurrence in HIV-infected individuals compared with non–HIV-infected individuals within a large US hospital database. Evidence from the study supports the notion that HIV-positive individuals are at increased risk of fracture.CrossRefPubMed
8.
Brown TT, Qaqish RB: Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006, 20:2165–2174.CrossRefPubMed
9.
Dubé MP, Qian D, Edmondson-Melancon H, et al.: Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis 2002, 35:475–481.CrossRefPubMed
10.
Jones S, Restrepo D, Kasowitz A, et al.: Risk factors for decreased bone density and effects of HIV on bone in the elderly. Osteoporos Int 2008, 19:913–918.CrossRefPubMed
11.
Brown TT, McComsey GA, King MS, et al.: Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009, 51:554–561.CrossRefPubMed
12.
Overton ET, Mondy K, Bush T, et al.: Factors associated with low bone mineral density in a large cohort of HIV-infected US adults: baseline results from the SUN study [abstract]. Presented at the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA; February 25–28, 2007.
13.
Aukrust P, Haug CJ, Ueland T, et al.: Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 1999, 84:145–150.CrossRefPubMed
14.
Alsina M, Guise TA, Roodman GD: Cytokine regulation of bone cell differentiation. Vitam Horm 1996, 52:63–98.CrossRefPubMed
15.
Abbas S, Zhang YH, Clohisy JC, Abu-Amer Y: Tumor necrosis factor-alpha inhibits pre-osteoblast differentiation through its type-1 receptor. Cytokine 2003, 22:33–41.CrossRefPubMed
16.
Blair HC, Robinson LJ, Zaidi M. Osteoclast signalling pathways. Biochem Biophys Res Commun 2005, 328:728–738.CrossRefPubMed
17.
Kostenuik PJ, Shalhoub V: Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 2001, 7:613–635.CrossRefPubMed
18.
Nguyen L, Dewhirst FE, Hauschka PV, Stashenko P: Interleukin-1 beta stimulates bone resorption and inhibits bone formation in vivo. Lymphokine Cytokine Res 1991, 10:15–21.PubMed
19.
Panagakos FS, Hinojosa LP, Kumar S: Formation and mineralization of extracellular matrix secreted by an immortal human osteoblastic cell line: modulation by tumor necrosis factor-alpha. Inflammation 1994, 18:267–284.CrossRefPubMed
20.
21.
Roodman GD: Role of cytokines in the regulation of bone resorption. Calcif Tissue Int 1993, 53(Suppl 1):S94–S98.CrossRefPubMed
22.
Gibellini D, De Crignis E, Ponti C, et al.: HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation. J Med Virol 2008, 80:1507–1514.CrossRefPubMed
23.
Fakruddin JM, Laurence J: HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem 2003, 278:48251–48258.CrossRefPubMed
24.
Fakruddin JM, Laurence J: Interactions among human immunodeficiency virus (HIV)-1, interferon-gamma and receptor of activated NF-kappa B ligand (RANKL): implications for HIV pathogenesis. Clin Exp Immunol 2004, 137:538–545.CrossRefPubMed
25.
Fakruddin JM, Laurence J: HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol 2005, 150:67–78.CrossRefPubMed
26.
Cotter EJ, Malizia AP, Chew N, et al.: HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development. AIDS Res Hum Retroviruses 2007, 23:1521–1530.CrossRefPubMed
27.
Cotter EJ, Ip HS, Powderly WG, Doran PP: Mechanism of HIV protein induced modulation of mesenchymal stem cell osteogenic differentiation. BMC Musculoskelet Disord 2008, 9:33.CrossRefPubMed
28.
Grund B, Peng G, Gibert CL, et al.: Continuous antiretroviral therapy decreases bone mineral density. AIDS 2009, 23:1519–1529.CrossRefPubMed
29.
Bolland MJ, Grey AB, Horne AM, et al.: Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years. Clin Endocrinol (Oxf) 2007, 67:270–275.CrossRef
30.
Dolan SE, Kanter JR, Grinspoon S: Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 2006, 91:2938–2945.CrossRefPubMed
31.
Duvivier C, Kolta S, Assoumou L, et al.: Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009, 23:817–824.CrossRefPubMed
32.
Fakruddin JM, Yin M, Laurence J: Pathophysiologic correlates of RANKL deregulation in HIV infection and its therapy [abstract]. Presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 22–25, 2005.
33.
Woodward CL, Hall AM, Williams IG, et al.: Tenofovir-associated renal and bone toxicity. HIV Med 2009, 10:482–487.CrossRefPubMed
34.
Purdy JB, Gafni RI, Reynolds JC, et al.: Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr 2008, 152:582–584.CrossRefPubMed
35.
Martin A, Bloch M, Amin J, et al.: Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009, 49:1591–1601.CrossRefPubMed
36.
Pan G, Kilby M, McDonald JM: Modulation of osteoclastogenesis induced by nucleoside reverse transcriptase inhibitors. AIDS Res Hum Retroviruses 2006, 22:1131–1141.CrossRefPubMed
37.
Tebas P, Yarasheski K, Henry K, et al.: Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retroviruses 2004, 20:589–594.CrossRefPubMed
38.
Gallant JE, Staszewski S, Pozniak AL, et al.: Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004, 292:191–201.CrossRefPubMed
39.
Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, et al.: Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses 2008, 24:1375–1382.CrossRef
40.
Rodrîguez M, Daniels B, Gunawardene S, Robbins GK: High frequency of vitamin D deficiency in ambulatory HIV-positive patients. AIDS Res Hum Retroviruses 2009, 25:9–14.CrossRefPubMed
41.
Haug C, Muller F, Aukrust P, Froland SS: Subnormal serum concentration of 1,25-vitamin D in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival. J Infect Dis 1994, 169:889–893.PubMed
42.
Haug CJ, Aukrust P, Haug E, et al.: Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab 1998, 83:3832–3838.CrossRefPubMed
43.
Cozzolino M, Vidal M, Arcidiacono MV, et al.: HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS 2003, 17:513–520.CrossRefPubMed
44.
45.
Arnsten JH, Freeman R, Howard AA, et al.: Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 2007, 21:617–623.CrossRefPubMed
46.
Mondy K, Powderly WG, Claxton SA, et al.: Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr 2005, 38:426–431.CrossRefPubMed
47.
Negredo E, Martinez-López E, Paredes R, et al.: Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. AIDS 2005, 19:343–345.PubMed
48.
Guaraldi G, Orlando G, Madeddu G, et al.: Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. HIV Clin Trials 2004, 5:269–277.CrossRefPubMed
49.
• Huang J, Meixner L, Fernandez S, McCutchan JA: A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS 2009, 23:51–57. This study highlights the beneficial effect of bisphosphonate therapy in HIV-positive individuals with loss of BMD who are at risk of fracture.CrossRefPubMed
Metadata
Title
Bone Changes and Fracture Risk in Individuals Infected With HIV
Authors
Amy H. Warriner
Michael J. Mugavero
Publication date
01-06-2010
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 3/2010
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-010-0099-9

Other articles of this Issue 3/2010

Current Rheumatology Reports 3/2010 Go to the issue

ReviewPaper

Drug-related Myopathies of Which the Clinician Should Be Aware

ReviewPaper

Theories of the Pathogenesis of Inclusion Body Myositis

ReviewPaper

Cutaneous Manifestations of Dermatomyositis and Their Management

ReviewPaper

Mechanical Factors and Bone Health: Effects of Weightlessness and Neurologic Injury

ReviewPaper

Dermatomyositis and Type 1 Interferons

ReviewPaper

The Societal Burden of Osteoporosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits